 |
인쇄하기
취소
|
Hanmi’s U.S. partner starts phase-2 trial for long-acting LAPS-GCSF in patients with breast cancer
Hanmi’s U.S. partner starts phase-2 trial for long-acting LAPS-GCSF in patients with breast cancer
Hanmi Pharmaceutical Co. said Tuesday that its U.S. partner Spectrum Pharmaceuticals has initiated a Phase-2 clinical program for SPI-2012 (also referred to as “LAPS-GCSF”), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes Hanmi‘s LAPSCOVERY™ (Long Acting Pro...
Hanmi Pharmaceutical Co. said Tuesday that its U.S. partner Spectrum Pharmaceuticals has initiated a Phase-2 clinical program for SPI-2012 (also referred to as “LAPS-GCSF”), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes Hanmi‘s LAPSCOVERY™ (Long Acting Pro...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.